Format

Send to

Choose Destination
Transfusion. 2010 Jan;50(1):240-2. doi: 10.1111/j.1537-2995.2009.02374.x. Epub 2009 Sep 16.

Expensive blood safety initiatives may offer less benefit than we think.

Author information

1
Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark. mka@ssi.dk

Abstract

BACKGROUND:

Various blood safety initiatives have ensured a historically low risk of infection transmission through blood transfusion. Although further prevention of infection transmission is possible through, for example, nucleic acid testing and future introduction of pathogen inactivation, such initiatives are very costly in relation to the benefit they offer. Although estimation of the cost-effectiveness requires detailed information about the survival of transfusion recipients, previous cost-effectiveness analyses have relied on incorrect survival assumptions.

STUDY DESIGN AND METHODS:

Based on empirical data of more than 1 million Scandinavian transfusion recipients followed for up to 20 years, we present two new survival functions. In a fictitious example we assessed the impact of survival assumptions on the estimated costs per quality-adjusted life-year (QALY) gained, by using the survival functions of three previous cost-effectiveness analyses along with the two new survival functions.

CONCLUSIONS:

We conclude that despite considerable costs, previous cost-effectiveness studies may have underestimated the costs per QALY gained by as much as 44%.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center